Medolife has completed extensive pre-clinical and clinical research on Escozine® as a potential therapeutic for various types of cancer. After observing the research and reviewing the data, the esteemed doctor made a formal recommendation to begin use of Escozine® in cancer therapies. He came to the conclusion, as noted in his formal recommendation, after making clinical observations that patients who used Escozine® as a part of their cancer therapeutics regimen saw:
- Improvements in their quality of life
- Decreased intensity of pain in affected areas
- Decreases in the diameter of tumor masses
- Improvement in their sleep conditions
- Prolonged life span
- No observed side effects
The doctor also endorsed further clinical investigations on Escozine® as a cancer therapeutic, which Medolife is currently conducting in both the United States and the Dominican Republic. It recently announced pre-clinical results on Escozine’s efficacy in eliminating cell lines in ovarian and bladder cancer whereas it eradicated the cell lines completely, creating a path forward for Escozine® as a cancer-fighting drug, along with its life-improvement benefits.
“After having witnessed the positive effects that Escozine® had on patients with cancer in pre-clinical studies, Dr. Feliz was so impressed he took it upon himself to recommend its use almost immediately,” said Medolife CEO Dr. Arthur Mikaelian. “While we must continue our official clinical research in order to obtain regulatory approval for Escozine® as a cancer therapeutic, it is becoming more clear that it is not only effective in improving the lives of cancer patients but also in fighting cancer itself. This is beyond encouraging. We are so appreciative of Dr. Feliz’s support and plan to continue to work with him and other researchers to further prove Escozine’s efficacy and bring products to market as quickly as possible. Many patients desperately need access and we will fulfill our mission of bringing life-saving therapeutics to patients who need them most.”
Escozine® is Medolife’s lead drug candidate that is undergoing clinical trials for both cancer and SARS-CoV-2 (COVID-19) therapeutics. It is derived from a small molecular peptide found in scorpions that is then polarized through a patented process developed by Medolife’s founder Dr. Mikaelian. The polarization process increases the efficacy and bioavailability of the active pharmaceutical ingredients in any polarized drug, requiring less dosage and leading to a decrease in side effects. Currently, Medolife is awaiting product registration for Escozine® in the Dominican Republic as a treatment for COVID-19. It has also filed data on Escozine® with the United States Food and Drug Administration (FDA) where it is seeking an Investigational New Drug (IND) approval pathway.
$QNTA
Surrounded by thieves, lets fight our way out!
